Inclusion Criteria:

• Patients ≥ 18 years at cancer diagnosis
• Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations
• Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction [PCR] based next generation sequencing [NGS], immunohistochemistry [IHC], fluorescence in situ hybridization [FISH], liquid biopsy)
• Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment

Exclusion Criteria:

• Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent